Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PragmatiCLL: Orelabrutinib Fixed-Cycle Regimen vs BTKi Monotherapy in Untreated CLL/SLL
NCT06476899Phase 2Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of orelabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06476899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06476899.